News
11-22-2010, 07:11 AM
S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.
More... (http://www.news-medical.net/news/20101122/SBIOs-SB1317-enters-Phase-1-clinical-trial-in-patients-with-advancedrefractory-hematologic-malignancies.aspx)
More... (http://www.news-medical.net/news/20101122/SBIOs-SB1317-enters-Phase-1-clinical-trial-in-patients-with-advancedrefractory-hematologic-malignancies.aspx)